AU Patent

AU2019232937A1 — Ceritinib formulation

Assigned to Novartis AG · Expires 2019-10-10 · 7y expired

What this patent protects

H:\dar\[nerwvoven\NRPortbl\DCC\DAR\16871920_.doex-26/04/2018 Abstract The present disclosure relates to a new pharmaceutical composition comprising Ceritinib. Particularly it is directed to the tablet that is prepared by wet granulation, wherein povidone is used as a binder. Furt…

USPTO Abstract

H:\dar\[nerwvoven\NRPortbl\DCC\DAR\16871920_.doex-26/04/2018 Abstract The present disclosure relates to a new pharmaceutical composition comprising Ceritinib. Particularly it is directed to the tablet that is prepared by wet granulation, wherein povidone is used as a binder. Further feature of the composition is that the drug and the binder form the inner phase, whereas all other excipients are added in a powder form as an outer phase. This way, the sticking of the composition is prevented and sufficient tablet hardness can be reached. Figure 1 LDK378 tablet 150MG - compression hardness profile -50 SExample3B -- Example4 I# 20_ _ -4- Example 5 -*-Example 6 5 10 15 20 25 30 Mean compression force [kN]

Drugs covered by this patent

Patent Metadata

Patent number
AU2019232937A1
Jurisdiction
AU
Classification
—
Expires
2019-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.